TY - JOUR
T1 - Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies
T2 - A meta-analysis of randomized clinical trials
AU - Ghatalia, Pooja
AU - Je, Youjin
AU - Nguyen, Paul L.
AU - Trinh, Quoc Dien
AU - Choueiri, Toni K.
AU - Sonpavde, Guru
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95% CI 1.22-1.49, p<. 0.001) and 1.33 (95% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2% (95% CI 31.8-45.1) and 4.0% (95% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.
AB - A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95% CI 1.22-1.49, p<. 0.001) and 1.33 (95% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2% (95% CI 31.8-45.1) and 4.0% (95% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.
KW - Fatigue
KW - Mammalian target of rapamycin inhibitors
KW - Meta-analysis
KW - Tyrosine kinase inhibitors
KW - Vascular endothelial growth factor receptor
UR - http://www.scopus.com/inward/record.url?scp=84937514381&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2015.03.006
DO - 10.1016/j.critrevonc.2015.03.006
M3 - Review article
C2 - 25900071
AN - SCOPUS:84937514381
SN - 1040-8428
VL - 95
SP - 251
EP - 263
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 2
ER -